The International Journal of Neuropsychopharmacology
September 9, 2026
Sota Tomiyama, K Yonezawa, K Kusudo et al.
Abstract Background Cognitive dysfunction is associated with impaired psychosocial functioning in patients with major depressive disorder (MDD). Patients with treatment-resistant depression (TRD) exhibit more pronounced cognitive dysfunction than those with non-resistant MDD, underscoring the need for effective therapeutic strategies. Psilocybin has emerged as a promising treatment for...
The International Journal of Neuropsychopharmacology
September 9, 2026
Z Wang, W Chen, C Hu et al.
Abstract Background Within the rapidly expanding field of psychedelic research, psilocybin, along with its active metabolite psilocin, has emerged as a highly promising candidate in the search for innovative treatments for neuropsychiatric disorders. In this context, preclinical research using animal disease models has produced somewhat inconsistent results when employing standard tests to...
The International Journal of Neuropsychopharmacology
September 9, 2026
Lisa Harada, K Yonezawa, K Kusudo et al.
Abstract Background Despite sequential treatments with conventional antidepressants, many patients with depression experience insufficient clinical improvement, referred to as treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic acting as a 5-HT2A receptor agonist, has attracted increasing attention as a novel treatment, with clinical trials demonstrating rapid and...
The International Journal of Neuropsychopharmacology
September 9, 2026
V Bruno, Martha López-canul, B Richardson et al.
Abstract Background Psilocybin has shown therapeutic potential for several neuropsychiatric disorders; however, concerns remain regarding its abuse liability and long-term neurobiological effects following repeated use. While acute psychedelic administration is generally considered to have low addictive potential, the consequences of repeated exposure on reward processing, withdrawal-related...
Revista Brasileira de Psiquiatria
September 9, 2026
Lisbeth Strandberg, Thiago P Fernandes, Irina I Shoshina et al.
Smoking cessation outcomes are heterogeneous, and factors associated with these differences are not fully understood. We examined longitudinal smoking trajectories across distinct smoking profiles and evaluated whether early craving and affective symptom changes were associated with verified abstinence. Participants in this observational cohort were classified as dependence-predominant or...
The International Journal of Neuropsychopharmacology
September 9, 2026
Orla Mallon
Abstract Background Opioid Use Disorder (OUD) is associated with substantial morbidity and mortality, with relapse remaining common despite the availability of opioid agonist and antagonist pharmacotherapies. Scotland continues to experience a disproportionate burden of drug-related deaths relative to other parts of the United Kingdom and Europe, reflecting the ongoing clinical and public...
The International Journal of Neuropsychopharmacology
September 9, 2026
G Goodwin
Abstract Background There are no approved medications for treating anorexia nervosa (AN) despite having the highest mortality rate of all psychiatric conditions. Talk therapies have limited efficacy, with relapse rates as high as 52% and poor long-term outcomes. Aims & Objectives This study evaluated the effects and safety of COMP360 psilocybin, a novel treatment, in individuals with anorexia...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
September 9, 2026
Alexandre Seillier, Ghinwa Ibrahim El Dannan, Lenka Seillier
Psilocybin, a tryptamine alkaloid found naturally in numerous Psilocybe mushroom species, is currently being investigated for its therapeutic potential in treating several neurobehavioral and psychiatric diseases. Our previous data showed that the 5-HT2B receptor (5-HT2BR) immobility and increases in climbing behavior in the forced swim test (FST), revealing that psilocybin's predictive...
arXiv (Cornell University)
September 8, 2026
Sai Jayakumar
preprint
Understanding why individuals respond differently to psilocybin requires modeling the drug's transcriptional perturbation signature at the cell-type level. I present a Transformer-based delta expression encoder that learns to classify differential gene expression status - upregulated, downregulated, or neutral - from single-nucleus RNA-sequencing data, without supervision from pathway...
Journal of Psychopharmacology
September 4, 2026
Marek Nikolič, Tom Froese, Pedro A. M. Mediano et al.
Background: Psilocybin’s therapeutic potential is neurophysiologically characterized by acute alpha power reductions and increased entropy. However, the systematic time-course of these changes from administration through the 24-hour sub-acute phase remains poorly characterized. Methods: In a double-blind, placebo-controlled, crossover trial ( N = 20, 10 females), healthy participants received a...